mardi 18 décembre 2018

Onco Actu du 18 décembre 2018

2. Etiologie

Johnson & Johnson shares slip after talc asbestos claims [The Guardian]

Baby Powder’s Possible Asbestos Link Worried Johnson & Johnson for Years [NY Times]

Special Report: J&J knew for decades that asbestos lurked in its Baby Powder [Reuters]

J&J moves to limit impact of Reuters report on asbestos in Baby Powder [Reuters]

3.1.1 Prévention - Tabac - e-cigs

Vapers inhale lower levels of toxins than smokers [Reuters]

E-cigarette usage nearly doubles in U.S. high-schools: survey [Reuters]

Study Shows Big Rise in Teen Vaping This Year [NY Times]

Teens using vaping devices in record numbers [NIH]

4.9 Dép., diag. & prono. - Sein

Breast cancer screening error 'overstated' [BBC News]

5.1 Traitements - Pré-clinique

Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells [NCI]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance [BMS]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Bellicum reports first data on ‘controllable’ CAR-T [FierceBiotech]

5.12.3 Immunothérapies-combinaisons

AstraZeneca wants a do-over on MYSTIC combo data. But a changeup in focus won’t end the death watch on this pairing [EndPoints]

5.12.6 Immunothérapies - AMM

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma [Merck]

Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest [EndPoints]

5.12.7 Immunothérapies - vaccins

Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer [FierceBiotech]

5.2.1 Pharma - Partenariats

Innovent buys Chinese rights to Incyte drugs for $40M upfront [FierceBiotech]

Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer [FierceBiotech]

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Amy Abernethy to join FDA as principal deputy commissioner [The Cancer Letter]

Amy Abernethy: Poised To Propel FDA Into Tech-Savvy, Patient-Centric Future [Forbes]

FDA Names Flatiron Health Executive Amy Abernethy Deputy Commissioner [Forbes]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA approves another Herceptin biosimilar in blow to Roche [BiopharmaDive]

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab) [Pfizer]

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [BMS]

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD [Takeda]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018 [EMA]

5.4 Traitements - Economie

The new Cancer Drugs Fund has quietly reached a significant milestone [Cancer Research UK]

5.5 ASCO

ASCO, ESMO Publish Joint Assessment of Their Value Frameworks [ASCO]

5.6.7 ESMO - Immunothérapies

Proton Pump Inhibitor Therapy Negatively Impacts the Efficacy of Nivolumab Plus Ipilimumab Combination Treatment in Melanoma [ESMO]

Neoadjuvant Ipilimumab plus Nivolumab Demonstrates Promising Overall Survival and Relapse-free Survival in Stage III Melanoma [ESMO]

Pembrolizumab Improves Long-term Overall Survival over Docetaxel in Advanced NSCLC [ESMO]

Data from the OAK Trial Show Fast Progression Is Not More Common with Atezolizumab [ESMO]

6.1 Observation

NIH scientists find that breast cancer protection from pregnancy starts decades later [NIH]

6.3 Associations/Fondations

Conflicts have killed trust in the system. Advocates must rebuild it [The Cancer Letter]

6.6 Publications

The 2018 Altmetric Top 100 [Altmetric]

6.8 Communication

Reflections on a 45-year career and 13 years leading [HealthNewsReview]

6.9 Controverses

The Parachute Trial: useful caricature or just a joke? [Unboxing Evidence Based Medicine]